PROBLEM TO BE SOLVED: To provide antibodies or fragments thereof that specifically bind to FcγRIIB, particularly human FcγRIIB, with greater affinity than they bind to FcγRIIA, particularly human FcγRIIA.SOLUTION: The present invention provides use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof.【課題】FcγRIIA、特にヒトFcγRIIAに結合する場合より大きな親和性で、FcγRIIB、特にヒトFcγRIIBに特異的に結合する、抗体またはその断片の提供。【解決手段】癌、好ましくはB細胞悪性疾患、特にB細胞慢性リンパ性白血病もしくは非ホジキンリンパ腫、自己免疫障害、炎症性障害、IgE媒介アレルギー障害、または一つもしくは複数のその症状の処置、予防、管理、または改善のための単剤治療としての抗FcγRIIB抗体またはその抗原結合断片の使用。【選択図】なし